Patents by Inventor Quanlai Song

Quanlai Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150191727
    Abstract: The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Michael T. Migawa, Punit P. Seth, Eric E. Swayze, Bruce S. Ross, Quanlai Song, Mingming Han
  • Patent number: 9012421
    Abstract: The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: April 21, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Punit P. Seth, Eric E. Swayze, Bruce S. Ross, Quanlai Song, Mingming Han
  • Patent number: 8530640
    Abstract: The present disclosure provides bicyclic cyclohexitol nucleoside analogs of formula I and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are expected to be useful for enhancing properties of oligomeric compounds including for example nuclease resistance.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: September 10, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael T. Migawa, Eric E. Swayze, Quanlai Song, Mingming Han, Bruce S. Ross
  • Publication number: 20120172414
    Abstract: The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.
    Type: Application
    Filed: August 5, 2010
    Publication date: July 5, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Punit P. Seth, Eric E. Swayze, Bruce S. Ross, Quanlai Song, Mingming Han
  • Publication number: 20110077390
    Abstract: The present disclosure provides bicyclic cyclohexitol nucleoside analogs of formula I and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are expected to be useful for enhancing properties of oligomeric compounds including for example nuclease resistance.
    Type: Application
    Filed: February 6, 2009
    Publication date: March 31, 2011
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Punit P. Seth, Michael T. Migawa, Eric E. Swayze, Quanlai Song, Mingmin Han, Bruce S. Ross
  • Patent number: 7427675
    Abstract: The present invention relates to oligonucleotide synthesis. In particular, the present invention provides methods for characterizing samples useful for making oligonucleotides.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: September 23, 2008
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Daniel C. Capaldi, Hans-Joachim Josef Gaus, Claus Andre Frank Rentel, Philip Dmitri Olsen, Christine C. Kurata, Quanlai Song
  • Publication number: 20080119645
    Abstract: The present invention is directed to amidites useful in the synthesis of oligonucleotides comprising at least one RN moiety, and to methods of using such amidites in the synthesis of such oligonucleotides. The inventive amidites possess surprising coupling efficiency as compared to prior art amidites, while providing convenient intermediates in the synthesis of oligonucleotides possessing at least one free 2?-OH moiety.
    Type: Application
    Filed: May 3, 2005
    Publication date: May 22, 2008
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Richard H. Griffey, Bruce S. Ross, Quanlai Song
  • Publication number: 20070276139
    Abstract: The present invention describes an improved hydroxyl protecting group of formula (1), wherein R2 and R7 are specified substituents and Q is O, S, NR10 or N(C?O)R10.
    Type: Application
    Filed: February 10, 2005
    Publication date: November 29, 2007
    Inventors: Quanlai Song, Sak Khammungkhune, Bruce Ross, Richard Griffey
  • Patent number: 7125855
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: October 24, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Balkrishen Bhat, Neelima Bhat, Anne B. Eldrup, Thazha P. Prakash, Marija Prhavc, Quanlai Song, Phillip Dan Cook, Steven S. Carroll, Malcolm Maccoss, David B. Olsen
  • Patent number: 7057062
    Abstract: A scalable process for purification of phosphorodiamidite includes steps of solubilizing a crude phosphorodiamidite in an apolar organic solvent, contacting the non-polar organic solvent with a polar phase comprising a polar organic solvent to remove impurities from the solubilized phosphorodiamidite, and removing the non-polar organic solvent from the phosphorodiamidite.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: June 6, 2006
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Quanlai Song, Bruce Ross
  • Patent number: 7030230
    Abstract: A process of purifying phosphoramidite precursors useful in inter alia synthesis of oligonucleotides comprises dissolving a crude phosphoramidite in a polar phase, adding a basic compound to the polar phase, adding a portion of water to the polar phase, contacting the polar phase with a first apolar phase to extract impurity into the apolar phase, separating the first apolar phase from the polar phase, adding a second aliquot of water to the polar phase, and contacting the polar phase with a second apolar phase, whereby the phosphoramidite partitions into the second apolar phase.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: April 18, 2006
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Bruce Ross, Quanlai Song
  • Patent number: 7019127
    Abstract: A process for the synthesis in solution phase of a phosphorothioate triester is provided. The process comprises the solution phase coupling of an H-phosphonate with an alcohol in the presence of a coupling agent to form an H-phosphonate diester. The H-phosphonate diester is oxidised in situ with a sulfur transfer agent to produce the phosphorothioate triester. Preferably, the H-phosphonate and alcohol are protected nucleosides or oligonucleotides. Oligonucleotide H-phosphonates which can be used in the formation of phosphorothioate triesters are also provided.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: March 28, 2006
    Assignee: Avecia Limited
    Inventors: Colin Bernard Reese, Quanlai Song
  • Publication number: 20060040308
    Abstract: The present invention relates to oligonucleotide synthesis. In particular, the present invention provides methods for characterizing samples useful for making oligonucleotides.
    Type: Application
    Filed: August 22, 2005
    Publication date: February 23, 2006
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Daniel Capaldi, Hans-Joachim Gaus, Claus Rentel, Philip Olsen, Christine Kurata, Quanlai Song
  • Patent number: 7002006
    Abstract: A process of manufacturing protected nucleosides comprises reacting a nucleoside with a protecting reagent in the presence of a regioselective activator to produce a regioselectively protected nucleoside. In some embodiments of the inventive method, an optionally substituted trityl or optionally substituted pixyl group is selectively added to the 5?-O-position of a nucleoside in the presence of lutidine as activator or activator/solvent. The inventive method results in improved selectivity of the 5?-O-position over the 3?-O-position, thereby improving overall product yield and purity, and permitting simplified purification protocols, in some cases obviating the need for chromatography to produce a purified protected nucleoside suitable for automated synthesis of oligonucleotides, such as primers, probes and antisense molecules.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: February 21, 2006
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Quanlai Song, Bruce S. Ross
  • Publication number: 20050240015
    Abstract: A process for the synthesis in solution phase of a phosphorothioate triester is provided. The process comprises the solution phase coupling of an H-phosphonate with an alcohol in the presence of a coupling agent to form an H-phosphonate diester. The H-phosphonate diester is oxidised in situ with a sulfur transfer agent to produce the phosphorothioate triester. Preferably, the H-phosphonate and alcohol are protected nucleosides or oligonucleotides. Oligonucleotide H-phosphonates which can be used in the formation of phosphorothioate triesters are also provided.
    Type: Application
    Filed: June 28, 2005
    Publication date: October 27, 2005
    Applicant: Avecia Limited
    Inventors: Colin Reese, Quanlai Song
  • Patent number: 6884881
    Abstract: A process for the preparation of a compound of formula (1): is provided, which comprises the reaction a compound of formula (2): with a compound of formula Al(OR)3 under substantially anhydrous conditions. X, and X1 are each independently H or a protecting group, B is a base; R is an alkyl, alkoxyalkyl, alkenyl or alkynyl group, each of which may be optionally substituted, and L is a leaving group.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: April 26, 2005
    Assignee: Avecia Limited
    Inventors: Colin Bernard Reese, Quanlai Song
  • Patent number: 6809195
    Abstract: The present invention discloses methods for synthesizing oligomeric compounds. The methods include a modified phosphoramidite protocol wherein the oxidation and capping steps are combined into a single step. The methods result in increased efficiency and are especially amenable to the large scale synthesis of oligomeric compounds.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: October 26, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Yogesh S. Sanghvi, Quanlai Song
  • Publication number: 20040198972
    Abstract: The present invention discloses methods for synthesizing oligomeric compounds. The methods include a modified phosphoramidite protocol wherein the oxidation and capping steps are combined into a single step. The methods result in increased efficiency and are especially amenable to the large scale synthesis of oligomeric compounds.
    Type: Application
    Filed: April 21, 2004
    Publication date: October 7, 2004
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Yogesh S. Sanghvi, Quanlai Song
  • Patent number: 6777395
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: August 17, 2004
    Assignees: Merck & Co., Inc., Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Neelima Bhat, Anne B. Eldrup, Thazha P. Prakash, Marija Prhavc, Quanlai Song, Phillip Dan Cook, Steven S. Carroll, Malcolm Maccoss, David B. Olsen
  • Publication number: 20040158055
    Abstract: A process of manufacturing protected nucleosides comprises reacting a nucleoside with a protecting reagent in the presence of a regioselective activator to produce a regioselectively protected nucleoside. In some embodiments of the inventive method, an optionally substituted trityl or optionally substituted pixyl group is selectively added to the 5′-O-position of a nucleoside in the presence of lutidine as activator or activator/solvent. The inventive method results in improved selectivity of the 5′-O-position over the 3′-O-position, thereby improving overall product yield and purity, and permitting simplified purification protocols, in some cases obviating the need for chromatography to produce a purified protected nucleoside suitable for automated synthesis of oligonucleotides, such as primers, probes and antisense molecules.
    Type: Application
    Filed: February 12, 2003
    Publication date: August 12, 2004
    Inventors: Quanlai Song, Bruce S. Ross